Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
A Phase II Study of Continuous Oral mTOR Inhibitor Everolimus for Recurrent, Radiographic-Progressive Neurofibromatosis Type 1–Associated Pediatric Low-Grade Glioma: A Neurofibromatosis Clinical Trials Consortium StudyNeuro-oncology 2020 Oct 14;22(10)1527-1535, NJ Ullrich, SP Prabhu, AT Reddy, MJ Fisher, R Packer, S Goldman, NJ Robison, DH Gutmann, DH Viskochil, JC Allen, B Korf, A Cantor, G Cutter, C Thomas, JP Perentesis, T Mizuno, AA Vinks, PE Manley, SN Chi, MW Kieran
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.